187 related articles for article (PubMed ID: 21738089)
21. Intravitreal bevacizumab (Avastin) therapy for persistent diffuse diabetic macular edema.
Haritoglou C; Kook D; Neubauer A; Wolf A; Priglinger S; Strauss R; Gandorfer A; Ulbig M; Kampik A
Retina; 2006; 26(9):999-1005. PubMed ID: 17151486
[TBL] [Abstract][Full Text] [Related]
22. Intravitreal bevacizumab and/or macular photocoagulation as a primary treatment for diffuse diabetic macular edema.
Solaiman KA; Diab MM; Abo-Elenin M
Retina; 2010; 30(10):1638-45. PubMed ID: 20838357
[TBL] [Abstract][Full Text] [Related]
23. Phacoemulsification with intravitreal bevacizumab injection in diabetic patients with macular edema and cataract.
Akinci A; Batman C; Ozkilic E; Altinsoy A
Retina; 2009; 29(10):1432-5. PubMed ID: 19898181
[TBL] [Abstract][Full Text] [Related]
24. Concentration of vascular endothelial growth factor in aqueous humor of eyes with advanced retinopathy of prematurity before and after intravitreal injection of bevacizumab.
Nonobe NI; Kachi S; Kondo M; Takai Y; Takemoto K; Nakayama A; Hayakawa M; Terasaki H
Retina; 2009 May; 29(5):579-85. PubMed ID: 19430279
[TBL] [Abstract][Full Text] [Related]
25. Pharmacokinetics of bevacizumab after topical and intravitreal administration in human eyes.
Moisseiev E; Waisbourd M; Ben-Artsi E; Levinger E; Barak A; Daniels T; Csaky K; Loewenstein A; Barequet IS
Graefes Arch Clin Exp Ophthalmol; 2014 Feb; 252(2):331-7. PubMed ID: 24170282
[TBL] [Abstract][Full Text] [Related]
26. Changes in aqueous concentrations of various cytokines after intravitreal triamcinolone versus bevacizumab for diabetic macular edema.
Sohn HJ; Han DH; Kim IT; Oh IK; Kim KH; Lee DY; Nam DH
Am J Ophthalmol; 2011 Oct; 152(4):686-94. PubMed ID: 21782151
[TBL] [Abstract][Full Text] [Related]
27. Long-term effect of intravitreal bevacizumab (avastin) in patients with chronic diffuse diabetic macular edema.
Kook D; Wolf A; Kreutzer T; Neubauer A; Strauss R; Ulbig M; Kampik A; Haritoglou C
Retina; 2008 Oct; 28(8):1053-60. PubMed ID: 18779710
[TBL] [Abstract][Full Text] [Related]
28. Preparation, characterization, and in vivo evaluation of nanoliposomes-encapsulated bevacizumab (avastin) for intravitreal administration.
Abrishami M; Zarei-Ghanavati S; Soroush D; Rouhbakhsh M; Jaafari MR; Malaekeh-Nikouei B
Retina; 2009 May; 29(5):699-703. PubMed ID: 19430280
[TBL] [Abstract][Full Text] [Related]
29. Intravitreal injection of ranibizumab during cataract surgery in patients with diabetic macular edema.
Rauen PI; Ribeiro JA; Almeida FP; Scott IU; Messias A; Jorge R
Retina; 2012 Oct; 32(9):1799-803. PubMed ID: 22495327
[TBL] [Abstract][Full Text] [Related]
30. Angiogenic and inflammatory markers in the intraocular fluid of eyes with diabetic macular edema and influence of therapy with bevacizumab.
Funk M; Schmidinger G; Maar N; Bolz M; Benesch T; Zlabinger GJ; Schmidt-Erfurth UM
Retina; 2010 Oct; 30(9):1412-9. PubMed ID: 20711086
[TBL] [Abstract][Full Text] [Related]
31. Pharmacokinetics of intravitreal ranibizumab (Lucentis).
Bakri SJ; Snyder MR; Reid JM; Pulido JS; Ezzat MK; Singh RJ
Ophthalmology; 2007 Dec; 114(12):2179-82. PubMed ID: 18054637
[TBL] [Abstract][Full Text] [Related]
32. Comparison of two doses of intravitreal bevacizumab (Avastin) for treatment of macular edema secondary to branch retinal vein occlusion: results from the Pan-American Collaborative Retina Study Group at 6 months of follow-up.
Wu L; Arevalo JF; Roca JA; Maia M; Berrocal MH; Rodriguez FJ; Evans T; Costa RA; Cardillo J;
Retina; 2008 Feb; 28(2):212-9. PubMed ID: 18301025
[TBL] [Abstract][Full Text] [Related]
33. Intravitreal bevacizumab (avastin) injection alone or combined with triamcinolone versus macular photocoagulation as primary treatment of diabetic macular edema.
Soheilian M; Ramezani A; Bijanzadeh B; Yaseri M; Ahmadieh H; Dehghan MH; Azarmina M; Moradian S; Tabatabaei H; Peyman GA
Retina; 2007; 27(9):1187-95. PubMed ID: 18046223
[TBL] [Abstract][Full Text] [Related]
34. Combined cataract extraction and intravitreal bevacizumab in eyes with choroidal neovascularization resulting from age-related macular degeneration.
Furino C; Ferrara A; Cardascia N; Besozzi G; Alessio G; Sborgia L; Boscia F
J Cataract Refract Surg; 2009 Sep; 35(9):1518-22. PubMed ID: 19683147
[TBL] [Abstract][Full Text] [Related]
35. Pharmacokinetics of bevacizumab after topical, subconjunctival, and intravitreal administration in rabbits.
Nomoto H; Shiraga F; Kuno N; Kimura E; Fujii S; Shinomiya K; Nugent AK; Hirooka K; Baba T
Invest Ophthalmol Vis Sci; 2009 Oct; 50(10):4807-13. PubMed ID: 19324856
[TBL] [Abstract][Full Text] [Related]
36. Predicted biologic activity of intravitreal bevacizumab.
Stewart MW
Retina; 2007; 27(9):1196-200. PubMed ID: 18046224
[TBL] [Abstract][Full Text] [Related]
37. Visual outcomes and growth factor changes of two dosages of intravitreal bevacizumab for neovascular age-related macular degeneration: a randomized, controlled trial.
Lai TY; Liu DT; Chan KP; Luk FO; Pang CP; Lam DS
Retina; 2009 Oct; 29(9):1218-26. PubMed ID: 19934816
[TBL] [Abstract][Full Text] [Related]
38. Comparative therapy evaluation of intravitreal bevacizumab and triamcinolone acetonide on persistent diffuse diabetic macular edema.
Shimura M; Nakazawa T; Yasuda K; Shiono T; Iida T; Sakamoto T; Nishida K
Am J Ophthalmol; 2008 May; 145(5):854-61. PubMed ID: 18328456
[TBL] [Abstract][Full Text] [Related]
39. Role of combined cataract surgery and intravitreal bevacizumab injection in preventing progression of diabetic retinopathy: prospective randomized study.
Cheema RA; Al-Mubarak MM; Amin YM; Cheema MA
J Cataract Refract Surg; 2009 Jan; 35(1):18-25. PubMed ID: 19101420
[TBL] [Abstract][Full Text] [Related]
40. Intravitreal bevacizumab (avastin) for central and hemicentral retinal vein occlusions: IBeVO study.
Costa RA; Jorge R; Calucci D; Melo LA; Cardillo JA; Scott IU
Retina; 2007 Feb; 27(2):141-9. PubMed ID: 17290194
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
